|
In this newly released ToxChats© episode, Dr. Brian McIntosh of Covance describes these cells, how their safety or efficacy are evaluated, explains how these nontraditional precision medicines contribute to the patient’s journey and he shares his thoughts on the future of this type of cancer immunotherapy. (CAR)T cells, also known as chimeric antigen receptor T cells, have transformed the landscape of cancer treatment. Instead of a standard chemotherapy, CAR-T treatment involves taking a patient's blood cells, engineering them in a lab to specifically attack cancer cells, and then injecting them back in the patient. The advent of in silico and in vitro, has propelled our understanding of cancer biology and allowed us to make such leaps in cancer care.
CAR/T: New Modalities Paving the Way for Cancer
Select ToxChats© podcast episodes are available on iTunes and Google (search ToxChats), in addition, all episodes are on the ACT website. The podcasts report on cutting-edge news in toxicological research from around the globe, and feature interviews with experts and a review of current advances. We encourage you to listen to and follow ToxChats. We welcome any feedback or suggestions for future topics.
Thank you,
American College of Toxicology
11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191
Tel: 703.547.0875 | Fax: 703.438.3113 | Email: acthq@actox.org
You may view the ACT Privacy Policy, provide consent to ACT to email you communications or
unsubscribe to stop receiving further ACT communication.
Privacy Policy | Provide Consent | Unsubscribe
|